Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) Director Jonathan Silverstein sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $295.59, for a total value of $14,779,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on ICPT shares. Analysts at FBR Capital Markets initiated coverage on shares of Intercept Pharmaceuticals in a research note on Friday, August 15th. They set an “underperform” rating and a $172.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Intercept Pharmaceuticals to a “hold” rating in a research note on Thursday, August 14th. Finally, analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday, August 12th. They now have a $456.00 price target on the stock, up previously from $323.00. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $472.91.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 1.54% on Wednesday, hitting $295.27. 229,932 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a 52-week low of $45.40 and a 52-week high of $497.00. The stock’s 50-day moving average is $247.1 and its 200-day moving average is $290.9. The company’s market cap is $6.265 billion. Intercept Pharmaceuticals also was the target of a large decrease in short interest in August. As of August 15th, there was short interest totalling 595,961 shares, a decrease of 25.1% from the July 31st total of 795,445 shares. Based on an average daily volume of 1,067,623 shares, the short-interest ratio is presently 0.6 days. Currently, 4.2% of the shares of the stock are short sold.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-13.34 EPS for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.